Bristol-Myers, Emory to conduct clinical trials for investigational compounds

21st June 2012 (Last Updated June 21st, 2012 18:30)

Bristol-Myers Squibb Company has entered into a master clinical trial agreement with Emory University to advance the clinical development of Bristol-Myers' investigational compounds in the metropolitan Atlanta area, US.

BMS

Bristol-Myers Squibb has entered into a master clinical trial agreement with Emory University to advance the clinical development of Bristol-Myers' investigational compounds in the metropolitan Atlanta area, US.

The first studies under the agreement will focus on multiple clinical trial programmes in oncology.

Bristol-Myers global development and medical affairs senior vice president Brian Daniels said the partnership is aligned with the company's strategy, which holds the opportunity to selectively integrate the expertise of other organisations with its own to best meet the treatment needs of patients.

"Our expectation is that the shared commitment of providing innovative solutions for patients, the world-class talent at both organisations and the clinical trial expertise at Emory, will result in important advancements in the understanding of Bristol-Myers Squibb compounds and their potential for treating patients with devastating diseases, such as cancer," Daniels added.

The investigators from Emory University and affiliated institutions will conduct Phase II, Phase III and paediatric trials to advance the ongoing development of Bristol-Myers's investigational medicine portfolio, mainly in oncology, metabolics, hepatitis C and immunoscience.

The agreement is built on experiences between the two organisations in conducting organ transplantation and cancer clinical trials, according to Bristol-Myers.

Emory Woodruff Health Sciences Center research vice president and the Atlanta Clinical and Translational Science Institute principal investigator David Stephens said that through the partnership, the university works to provide a framework to improve clinical trials efficiency and to enhance the development of academic and industry collaborations that solve healthcare problems.

"Emory's successful partnership with Bristol-Myers Squibb in developing drugs for organ transplantation is an excellent example of the benefits of these kinds of collaborations," Stephens added.


Image: A Bristol-Myers Squibb R&D facility Princeton Rd, Princeton, New Jersey, US. Photo: Coolcaesar at en.wikipedia.